RPS6KB1 and leukemia: JAK1/2 inhibitor inactivated the mTOR/p70S6K/4EBP1 pathway and reduced the inhibitory phosphorylation of GSK3 in leukemia cell line, which correlated with JAK1/2 inhibitor reduction of proliferation and survival of these cells [39].